HCD
MCID: HVY001
MIFTS: 41

Heavy Chain Disease (HCD) malady

Categories: Blood diseases, Rare diseases, Immune diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Heavy Chain Disease

Aliases & Descriptions for Heavy Chain Disease:

Name: Heavy Chain Disease 12 56 42 14 69
Hcd 56

Characteristics:

Orphanet epidemiological data:

56
heavy chain disease
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060125
ICD10 33 C88.2
MeSH 42 D006362
Orphanet 56 ORPHA86864
MESH via Orphanet 43 D006362
UMLS via Orphanet 70 C0018852
ICD10 via Orphanet 34 C88.2 C88.3

Summaries for Heavy Chain Disease

Disease Ontology : 12 A hypersensitivity reaction type IV disease that results from a proliferation of cells producing immunoglobulin heavy chains.

MalaCards based summary : Heavy Chain Disease, also known as hcd, is related to delta chain disease and mu chain disease. An important gene associated with Heavy Chain Disease is IGHG3 (Immunoglobulin Heavy Constant Gamma 3 (G3m Marker)), and among its related pathways/superpathways are NF-kappaB Signaling and IL4-mediated signaling events. The drugs Carvedilol and Metoprolol have been mentioned in the context of this disorder. Affiliated tissues include small intestine, t cells and testes.

Wikipedia : 71 Heavy chain disease is a form of paraproteinemia with a proliferation of cells producing immunoglobulin... more...

Related Diseases for Heavy Chain Disease

Diseases in the Heavy Chain Disease family:

Gamma Heavy Chain Disease Alpha-Heavy Chain Disease

Diseases related to Heavy Chain Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
id Related Disease Score Top Affiliating Genes
1 delta chain disease 31.4 CD40LG CD79A
2 mu chain disease 30.5 CD40LG CD79A IGHG3 MYD88 PARD3 PNMT
3 gamma heavy chain disease 12.6
4 alpha-heavy chain disease 12.2
5 agammaglobulinemia 11.3
6 alpha chain disease 11.2
7 myosinopathies 11.0
8 lymphoma 10.2
9 paramyloidosis 10.1 CD40LG MYD88
10 alcoholic neuropathy 10.1 CD40LG CD79A
11 camptodactyly vertebral fusion 10.1 CD40LG CD79A
12 spinal polio 10.1 CD40LG CD79A
13 rabies 10.1 CD40LG CD79A
14 unilateral retinoblastoma 10.1 CD40LG CD79A
15 mesangial proliferative glomerulonephritis 10.1 CD40LG CD79A
16 discitis 10.1 CD40LG CD79A
17 spinal canal and spinal cord meningioma 10.1 CD40LG CD79A
18 trichostrongyloidiasis 10.1 CD40LG CD79A
19 angiosarcoma 10.1 CD40LG MYD88
20 colloid adenoma 10.1 CD40LG CD79A
21 heart septal defect 10.1 CD40LG CD79A
22 cutaneous polyarteritis nodosa 10.1 CD40LG CD79A
23 mild pre-eclampsia 10.1 CD40LG CD79A
24 retinal microaneurysm 10.1 CD40LG CD79A
25 pediatric meningioma 10.1 CD40LG CD79A
26 tonsil cancer 10.1 CD40LG CD79A
27 indomethacin antenatal infection 10.1 CD40LG CD79A
28 postcricoid region cancer 10.1 CD40LG CD79A
29 beach ear 10.1 CD40LG CD79A
30 acute kidney tubular necrosis 10.1 CD40LG CD79A
31 atheroembolism of kidney 10.1 CD40LG CD79A
32 partial sensory epilepsy 10.1 CD40LG CD79A
33 ritscher-schinzel syndrome 1 10.1 CD40LG CD79A
34 diabetic angiopathy 10.1 CD40LG CD79A
35 endocarditis 10.1 CD40LG CD79A
36 muscular dystrophy 10.1 CD40LG CD79A
37 dumping syndrome 10.1 CD40LG CD79A
38 striatonigral degeneration 10.1 CD40LG CD79A
39 ciliary body spindle cell melanoma 10.1 CD40LG CD79A
40 purulent endophthalmitis 10.1 CD40LG CD79A
41 generalized atherosclerosis 10.1 CD40LG CD79A
42 bursitis 10.1 CD40LG CD79A
43 syphilis 10.1 CD40LG CD79A
44 homocystinuria 10.1 CD40LG CD79A
45 mental retardation, autosomal dominant 19 10.1 CD40LG CD79A
46 hemangioma of orbit 10.1 CD40LG CD79A
47 leiomyosarcoma 10.1 CD40LG CD79A
48 immunoglobulin beta deficiency 10.1 CD40LG CD79A
49 gestational diabetes 10.1 CD40LG CD79A
50 odontogenic myxoma 10.1 CD40LG CD79A

Graphical network of the top 20 diseases related to Heavy Chain Disease:



Diseases related to Heavy Chain Disease

Symptoms & Phenotypes for Heavy Chain Disease

Drugs & Therapeutics for Heavy Chain Disease

Drugs for Heavy Chain Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 140)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
3
Doxazosin Approved Phase 4 74191-85-8 3157
4 Adrenergic Agents Phase 4
5 Adrenergic Antagonists Phase 4
6 Adrenergic alpha-1 Receptor Antagonists Phase 4
7 Adrenergic alpha-Antagonists Phase 4
8 Adrenergic beta-1 Receptor Antagonists Phase 4
9 Neurotransmitter Agents Phase 4,Phase 1,Phase 2
10 Adrenergic beta-Antagonists Phase 4
11 Sympatholytics Phase 4
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
13 Vasodilator Agents Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Antihypertensive Agents Phase 4
16 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
19
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
20
Palbociclib Approved Phase 2, Phase 3 571190-30-2 11431660 5005498 5330286
21
nivolumab Approved Phase 2, Phase 3,Phase 1 946414-94-4
22
Docetaxel Approved May 1996, Investigational Phase 2, Phase 3 114977-28-5 148124 9877265
23 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
24 Prednisolone acetate Phase 3
25 glucocorticoids Phase 3,Phase 1,Phase 2
26 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
27 Neuroprotective Agents Phase 3
28 Hormone Antagonists Phase 3,Phase 1,Phase 2
29 Hormones Phase 3,Phase 1,Phase 2
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 1,Phase 2
31 Pharmaceutical Solutions Phase 3
32 Immunoglobulin G Phase 3,Phase 2,Phase 1
33 Immunoglobulins Phase 3,Phase 2,Phase 1
34 Prednisolone hemisuccinate Phase 3
35 Prednisolone phosphate Phase 3
36 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
37 Protective Agents Phase 3
38 Antiemetics Phase 3,Phase 1,Phase 2
39 Anti-Inflammatory Agents Phase 3,Phase 1,Phase 2
40 Methylprednisolone acetate Phase 3
41 Methylprednisolone Hemisuccinate Phase 3
42 Antibodies Phase 3,Phase 2,Phase 1
43 Antineoplastic Agents, Hormonal Phase 3,Phase 1,Phase 2
44
Erlotinib Hydrochloride Phase 2, Phase 3 183319-69-9 176871
45 Antimitotic Agents Phase 2, Phase 3
46
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
47
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
48
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
49
Testosterone Approved, Investigational Phase 2 58-22-0 6013
50
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612

Interventional clinical trials:

(show top 50) (show all 58)
id Name Status NCT ID Phase
1 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
2 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4
3 Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02105961 Phase 3
4 Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients Completed NCT02105948 Phase 3
5 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma Completed NCT01691508 Phase 3
6 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3
7 S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3
8 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3
9 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Active, not recruiting NCT02135692 Phase 3
10 A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia Unknown status NCT00949988 Phase 1, Phase 2
11 A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT00464178 Phase 2
12 Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder Completed NCT01354314 Phase 1, Phase 2
13 Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Completed NCT00516412 Phase 2
14 Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis Completed NCT00621400 Phase 1, Phase 2
15 Assessing Free Immunoglobulin Light Chains in Patients With Myeloma Completed NCT00301275 Phase 2
16 MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB Completed NCT02643654 Phase 2
17 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2
18 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2
19 CFAR Study in Patients With Chronic Lymphocytic Leukemia Completed NCT00525603 Phase 2
20 Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed NCT01082939 Phase 2
21 HORMA: Hormonal Regulators of Muscle and Metabolism in Aging Completed NCT00183040 Phase 2
22 Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2 Completed NCT02059759 Phase 2
23 Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Recruiting NCT03011814 Phase 1, Phase 2
24 Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Recruiting NCT02794883 Phase 2
25 SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer Recruiting NCT02581787 Phase 1, Phase 2
26 Exercise For Sub-acute Stroke Patients in Jamaica Recruiting NCT01392391 Phase 2
27 S1400A Lung-Map: MEDI4736 as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Active, not recruiting NCT02766335 Phase 2
28 Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Not yet recruiting NCT02966587 Phase 2
29 Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Not yet recruiting NCT03038672 Phase 2
30 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation Not yet recruiting NCT02953457 Phase 1, Phase 2
31 Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer Not yet recruiting NCT02888743 Phase 2
32 Tocilizumab for Chronic Graft-versus-Host Disease Treatment Withdrawn NCT02174263 Phase 2
33 Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis Recruiting NCT02871323 Phase 1
34 JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Recruiting NCT02706405 Phase 1
35 Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Active, not recruiting NCT02925533 Phase 1
36 Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma Not yet recruiting NCT02914405 Phase 1
37 Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Withdrawn NCT00726466 Phase 1
38 Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia Unknown status NCT00917540
39 The Effects of Exercise Training on Shoulder Neuromuscular Control Unknown status NCT02164305
40 Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial Completed NCT01629745
41 Genetic Test To Identify Previously Undetectable Minimal Residual Disease in Cell Samples From Younger Patients With Acute Lymphoblastic Leukemia Completed NCT01533168
42 Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies. Completed NCT01715623
43 The Relationship Between Arsenic Methylation Capability and Blood Metals in Children With Developmental Delays Completed NCT02523989
44 A Study to Evaluate the Performance of a Diagnostic Test in ALS Recruiting NCT02759913
45 Mutations in Genes Associated With Pentalogy of Cantrell Recruiting NCT00083499
46 Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Recruiting NCT02827838
47 Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy Recruiting NCT01705626
48 Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy Recruiting NCT02995356
49 Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique Recruiting NCT02000635
50 Heavy Light Chain in Chronic Lymphocytic Leukemia Recruiting NCT02377869

Search NIH Clinical Center for Heavy Chain Disease

Cochrane evidence based reviews: heavy chain disease

Genetic Tests for Heavy Chain Disease

Anatomical Context for Heavy Chain Disease

MalaCards organs/tissues related to Heavy Chain Disease:

39
Small Intestine, T Cells, Testes, Thyroid, Skin, B Cells, Lymph Node

Publications for Heavy Chain Disease

Articles related to Heavy Chain Disease:

(show top 50) (show all 190)
id Title Authors Year
1
Gamma Heavy Chain Disease with T-cell Large Granular Lymphocytic Leukemia: A Case Report and Review of the Literature. ( 26875967 )
2016
2
T cell receptor rearrangements in a patient with I^-heavy chain disease: A case report. ( 27313757 )
2016
3
Discovery of a gamma heavy chain disease in a patient followed-up for a lymphoplasma cell proliferative disorder. ( 27237805 )
2016
4
Franklin's disease: immunoglobulin heavy chain disease. ( 27358869 )
2015
5
A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease. ( 25663537 )
2015
6
Gamma heavy chain disease associated with large granular lymphocytic leukemia: A report of two cases and review of the literature. ( 26222587 )
2015
7
Severe enteropathy caused by I+-heavy chain disease lacking detectable M-proteins. ( 24633028 )
2014
8
Alpha heavy chain disease: a rare lymphoma hard to diagnose. ( 25125965 )
2014
9
Gamma heavy chain disease: cytological diagnosis of a rare lymphoid malignancy facilitated by correlation with key laboratory findings. ( 25180407 )
2014
10
Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma. ( 24859878 )
2014
11
Unusual concurrence of T-cell large granular lymphocytic leukemia with Franklin disease (gamma heavy chain disease) manifested with massive splenomegaly. ( 22694793 )
2013
12
Analysis of patients with I^-heavy chain disease by the heavy/light chain and free light chain assays. ( 24327529 )
2013
13
Gamma heavy-chain disease: defining the spectrum of associated lymphoproliferative disorders through analysis of 13 cases. ( 22301495 )
2012
14
Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement. ( 22561184 )
2012
15
Gamma heavy chain disease in a patient with rheumatoid arthritis--a laboratory evaluation. ( 23092068 )
2012
16
Successful treatment of I^-heavy-chain disease with rituximab and fludarabine. ( 22890122 )
2012
17
Gamma heavy chain disease in a patient with diabetes and chronic renal insufficiency: diagnostic assessment of the heavy chain fragment. ( 18348312 )
2008
18
Capillary immunotyping electrophoresis and high resolution two-dimensional electrophoresis for the detection of mu-heavy chain disease. ( 18036562 )
2008
19
Combination of rituximab and chemotherapy showing anti-tumor effect in gamma heavy chain disease expressing CD20. ( 18839436 )
2008
20
Hypertrophic spinal pachymeningitis associated with heavy-chain disease. Case report. ( 17933324 )
2007
21
Multiple extranodal tumors in mu-heavy chain disease. ( 17050207 )
2006
22
Unusual gamma heavy chain disease protein in a patient with splenic marginal-zone lymphoma. ( 16536920 )
2006
23
Detection of heavy chain disease by capillary zone electrophoresis. ( 15976121 )
2005
24
Heavy chain disease can be detected by capillary zone electrophoresis. ( 15613723 )
2005
25
Successful treatment of mu-heavy chain disease with fludarabine monophosphate: a case report. ( 15005347 )
2004
26
Mu-heavy chain disease associated with systemic amyloidosis. ( 15203869 )
2004
27
A 59-year-old woman with immunotactoid glomerulopathy, heavy-chain disease, and non-hodgkin lymphoma. ( 15163227 )
2004
28
Gamma-heavy chain disease: review of 23 cases. ( 12861101 )
2003
29
Gamma heavy chain disease screening showing a discrepancy between electrophoretic and nephelometric determinations of serum gamma globulin concentration. ( 12227865 )
2002
30
Heavy chain disease. ( 12057070 )
2002
31
Test and teach. Laboratory characterisation of paraproteins. Heavy chain disease. ( 11523944 )
2001
32
Composite nodular lymphocyte-predominance Hodgkin disease and gamma-heavy-chain disease: a case report and review of the literature. ( 11371236 )
2001
33
Gamma heavy chain disease in man: independent structural abnormalities and reduced transcription of a functionally rearranged lambda L-chain gene result in the absence of L-chains. ( 10950937 )
2000
34
Is there a pathogenic link between gamma heavy chain disease and chronic arthritis? ( 10647957 )
2000
35
Alpha heavy chain disease in a child. ( 10881592 )
2000
36
Test and teach. Number One hundred and four. Mu heavy chain disease (mu-HCD). ( 10968396 )
2000
37
Alpha-heavy chain disease, Mediterranean lymphoma, and immunoproliferative small intestinal disease: a review of clinicopathological features, pathogenesis, and differential diagnosis. ( 10235185 )
1999
38
Chronic arthritis and gamma heavy chain disease: coincidence or pathogenic link? ( 9751465 )
1998
39
Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. ( 9482908 )
1998
40
A case of mu heavy-chain disease associated with hyperglobulinemia, anemia, and a positive Coombs test. ( 9858149 )
1998
41
A case of mu-heavy chain disease: combined features of mu-chain disease and macroglobulinemia. ( 9401282 )
1997
42
Cast nephropathy in mu heavy chain disease. ( 9285150 )
1997
43
Failure of anti-lambda immunofixation reagent mimics alpha heavy-chain disease. ( 7813064 )
1995
44
Pre-B-cell development in the absence of lambda 5 in transgenic mice expressing a heavy-chain disease protein. ( 8548286 )
1995
45
Malabsorption associated with a high-grade-malignant non-Hodgkin's lymphoma, alpha-heavy-chain disease and immunoproliferative small intestinal disease. ( 7793120 )
1995
46
Primary SjAPgren's syndrome and gamma heavy chain disease. ( 7991295 )
1994
47
Immunoproliferative small intestinal disease: Mediterranean lymphoma and alpha heavy chain disease. ( 8313111 )
1994
48
Free fragments of gamma chain in the urine. A possible source of confusion with gamma heavy-chain disease. ( 8160637 )
1994
49
First report of fludarabine in gamma-heavy chain disease. ( 7819086 )
1994
50
Modified immunoselection technique for definitive diagnosis of heavy-chain disease. ( 8149622 )
1994

Variations for Heavy Chain Disease

Expression for Heavy Chain Disease

Search GEO for disease gene expression data for Heavy Chain Disease.

Pathways for Heavy Chain Disease

Pathways related to Heavy Chain Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.63 CD40LG CD79A MYD88
2 11.06 CD40LG IGHG3
3 10.85 CD40LG MYD88
4 10.19 CD40LG CD79A

GO Terms for Heavy Chain Disease

Cellular components related to Heavy Chain Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.8 CD40LG CD79A IGHG3

Biological processes related to Heavy Chain Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 B cell differentiation GO:0030183 8.96 CD40LG CD79A
2 B cell proliferation GO:0042100 8.62 CD40LG CD79A

Sources for Heavy Chain Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....